Intact Investment Management Inc. Has $2.28 Million Stock Position in DexCom, Inc. $DXCM

Intact Investment Management Inc. boosted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 102.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 33,890 shares of the medical device company’s stock after acquiring an additional 17,190 shares during the quarter. Intact Investment Management Inc.’s holdings in DexCom were worth $2,280,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. grew its position in DexCom by 1.8% during the second quarter. Vanguard Group Inc. now owns 48,322,405 shares of the medical device company’s stock valued at $4,218,063,000 after purchasing an additional 866,506 shares in the last quarter. Jennison Associates LLC increased its stake in shares of DexCom by 9.4% in the second quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock worth $1,005,367,000 after acquiring an additional 994,300 shares during the last quarter. Geode Capital Management LLC boosted its position in DexCom by 3.4% during the second quarter. Geode Capital Management LLC now owns 10,766,356 shares of the medical device company’s stock valued at $936,100,000 after purchasing an additional 358,617 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in DexCom by 106.8% in the second quarter. Massachusetts Financial Services Co. MA now owns 6,605,687 shares of the medical device company’s stock valued at $576,610,000 after purchasing an additional 3,410,858 shares in the last quarter. Finally, Norges Bank acquired a new position in DexCom in the 2nd quarter worth about $453,279,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

DXCM has been the subject of several research reports. Evercore ISI initiated coverage on DexCom in a report on Tuesday, November 25th. They set an “in-line” rating and a $68.00 price target for the company. TD Cowen decreased their target price on shares of DexCom from $100.00 to $84.00 and set a “buy” rating for the company in a research report on Friday, October 31st. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of DexCom in a research note on Monday, December 29th. Robert W. Baird set a $82.00 target price on shares of DexCom in a research report on Friday, October 31st. Finally, UBS Group reduced their price target on DexCom from $106.00 to $95.00 and set a “buy” rating for the company in a research report on Monday, November 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, four have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $86.30.

DexCom Stock Up 0.7%

DexCom stock opened at $73.34 on Tuesday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.56 and a quick ratio of 1.38. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $93.25. The firm has a fifty day moving average price of $66.71 and a two-hundred day moving average price of $70.98. The firm has a market cap of $28.60 billion, a price-to-earnings ratio of 40.74, a P/E/G ratio of 1.31 and a beta of 1.48.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.04. DexCom had a return on equity of 30.65% and a net margin of 15.96%.The business had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.18 billion. During the same period in the previous year, the company posted $0.45 earnings per share. The firm’s revenue for the quarter was up 21.6% on a year-over-year basis. As a group, analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Activity

In related news, Director Bridgette P. Heller sold 1,012 shares of the business’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $58.07, for a total transaction of $58,766.84. Following the transaction, the director directly owned 27,031 shares in the company, valued at $1,569,690.17. The trade was a 3.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Richard Alexander Collins sold 2,906 shares of the firm’s stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $59.05, for a total value of $171,599.30. Following the completion of the sale, the director owned 35,088 shares of the company’s stock, valued at $2,071,946.40. This represents a 7.65% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 7,866 shares of company stock valued at $448,177. 0.32% of the stock is owned by company insiders.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.